Despite the complexity of the process, biopharmaceutical has become one of the fastest growing segments of the pharmaceutical industry due to its wide range of indications, including difficult conditions such as cancer, stroke or heart disease. In response to this industry trend, Boehringer Ingelheim is investing €35 billion to build a leading biopharmaceutical center (BDC) in Biberach Andries, Germany, the company’s largest single investment in Germany to date.
As the largest biotechnology development center in Europe, the campus has more than 7,000 employees and covers an area of approximately 34,500 square meters, bringing together scientists from different working and academic backgrounds to collaborate on the production and research of antibodies and therapeutic proteins. And focus on industrial production for clinical use and research.
Boehringer Ingelheim invests heavily in its drug discovery network. CPHI Pharmaceutical intermediates exhibition was informed that in the last fiscal year alone, the special investment has reached 500 million euros, of which the investment in Germany accounted for 47%.
BDC is the company’s largest research and development and production site, and the completion of the development center will be an important milestone in Boehringer Ingelheim’s development.
Hubertus von Baumbach, Chairman of Boehringer Ingelheim’s Board of Directors, said the investment is an important addition to the global biopharmaceutical research and development network, which will focus on the development and production of biotherapeutics.
At the opening ceremony of the park, Baden-Wurttemberg State Minister Winfried Kretschmann announced that the park will be dedicated to the research of a new generation of bioactive substances.
About Wisdom Drugs
Wisdom Drugs Co .,Ltd was founded in Sep. 2011 whose headquarter located in Changzhou Creative Industry Park, having a branch in India. The company’s R&D center is engaged in not only the process development of APIs, intermediates, poly-peptide compounds and heterocyclic compounds,but also the optimization and production. We are devoted to the synthesis customization and the technology transfer, enabling compounds to be scaled from laboratory to commercial to meet the requirements of different customers.
